Texas Medical Center Training Program in Antimicrobial Resistance
德克萨斯医学中心抗菌素耐药性培训计划
基本信息
- 批准号:10401444
- 负责人:
- 金额:$ 31.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY/ABSTRACT
The rise of antibiotic-resistant microorganisms globally has become a critical public health priority due to the
devastating consequences that it may have to the world health and economy. Indeed, antibiotic resistance
threatens the progress of medicine in all areas and, as such, the issue has reached the highest level of
government, including the Office of the US President (with the creation of the Presidential Advisory Council on
Combating Antibiotic-Resistant Bacteria) and the initiative for global action by the United Nations, among
others. Houston is the home to the largest cluster of healthcare institutions in the world, the Texas Medical
Center (TMC) with more than 9,200 hospital beds, receiving more than 8 million patient visits per year.
Additionally, the Houston area harbors a strong history of outstanding infectious diseases research and training
including that focused on antimicrobial resistance (AMR) and antibiotic stewardship. In the last two years, the
formation of the UTHealth Center for Antimicrobial Resistance and Microbial Genomics (CARMiG) and the
Gulf Coast Consortia (GCC) Cluster for Antimicrobial Resistance (GCC-AMR) has resulted in an active,
multidisciplinary and comprehensive research and educational program that has amalgamated the efforts of
AMR researchers and created the resources, personnel, funding and fertile ground to launch an ambitious,
innovative and unparalleled training program on AMR. We propose to establish the Texas Medical Center
Training Program on AMR (TPAMR) that seeks to train postdoctoral scholars, clinical residents and fellows
from seven geographically adjacent institutions in the TMC (University of Texas Health Science Center at
Houston, MD Anderson Cancer Center, Baylor College of Medicine, University of Texas Medical Branch, Rice
University, University of Houston, and Institute of Biosciences and Technology of Texas A&M University) on
advanced aspects of AMR research. We aim to take advantage of the strong expertise of the GCC on
successful T32 programs in other areas and the educational activities already in place at CARMiG, combined
with the expertise of world-class researchers on AMR in the TMC. TPAMR seeks to leverage all the available
resources to train the next generation of scientists and clinician-scientists (MDs, PhDs and PharmDs) focused
on tackling the pressing AMR public health crisis. The highly collaborative environment provides the perfect
opportunity for trainees to acquire the skills, expertise and intellectual abilities to foster innovative research that
has a strong translational component and could be developed to directly influence patient care. The focus of
expertise of the proposed training grant includes, i) molecular basis of antibiotic resistance, ii) bacterial
genomics and bioinformatics, iii) microbiome science, iv) pharmacological aspects of resistance, v) clinical
epidemiology and biostatistics of AMR and, vi) antibiotic stewardship. We believe that we are poised to
develop a unique, innovative and comprehensive training program that truly provide trainees with exceptional
tools and abilities and create a strong cohort of new world-class leaders on AMR.
项目总结/摘要
全球耐药性微生物的兴起已成为一个关键的公共卫生优先事项,
它可能对世界健康和经济造成的毁灭性后果。事实上,抗生素耐药性
威胁着医学在各个领域的进步,因此,这个问题已经达到了最高水平,
政府,包括美国总统办公室(随着总统顾问理事会的成立,
防治抗生素耐药性细菌)和联合国全球行动倡议,
他人休斯顿是世界上最大的医疗保健机构集群的所在地,
中心(TMC)拥有9,200多张病床,每年接待800多万人次的患者。
此外,休斯顿地区拥有优秀的传染病研究和培训的强大历史
包括关注抗菌素耐药性(AMR)和抗生素管理的研究。在过去的两年里,
UTHealth抗菌素耐药性和微生物基因组学中心(CARMiG)和
墨西哥湾沿岸财团(GCC)抗菌素耐药性集群(GCC-AMR)已经导致了一个活跃的,
多学科和全面的研究和教育计划,已合并的努力,
AMR的研究人员,并创造了资源,人员,资金和肥沃的土壤,推出一个雄心勃勃的,
创新和无与伦比的AMR培训计划。我们建议建立德克萨斯医疗中心
AMR培训计划(TPAMR)旨在培训博士后学者,临床住院医师和研究员
来自TMC(德克萨斯大学健康科学中心,
休斯敦,MD安德森癌症中心,贝勒医学院,德克萨斯大学医学分支,赖斯
美国德克萨斯A& M大学生物科学与技术研究所(Institute of Biosciences and Technology of Texas A&M University)
AMR研究的先进方面。我们的目标是利用海湾合作委员会的强大专业知识,
成功的T32计划在其他领域和教育活动已经到位,在CARMiG,结合
拥有TMC世界级AMR研究人员的专业知识。TPAMR寻求利用所有可用的
重点培训下一代科学家和临床科学家(医学博士、博士和药学博士)的资源
应对紧迫的AMR公共卫生危机。高度协作的环境提供了完美的
为学员提供获得技能、专门知识和智力的机会,以促进创新研究,
具有很强的翻译成分,可以直接影响病人的护理。的焦点
拟议培训补助金的专业知识包括:i)抗生素耐药性的分子基础,ii)细菌
基因组学和生物信息学,iii)微生物组科学,iv)耐药性的药理学方面,v)临床
AMR的流行病学和生物统计学,以及,vi)抗生素管理。我们相信我们已经准备好
开发一个独特的,创新的和全面的培训计划,真正为学员提供卓越的
工具和能力,并在AMR方面创造一个强大的新的世界级领导者队伍。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anthony Richard Flores其他文献
Anthony Richard Flores的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anthony Richard Flores', 18)}}的其他基金
Evolution and pathogenesis of serotype V group B Streptococcus in humans
人类血清型 B 型链球菌的进化和发病机制
- 批准号:
10355538 - 财政年份:2021
- 资助金额:
$ 31.18万 - 项目类别:
Defining novel mechanisms of clonal emergence in Group A Streptococcus
定义 A 组链球菌克隆出现的新机制
- 批准号:
10189994 - 财政年份:2021
- 资助金额:
$ 31.18万 - 项目类别:
Evolution and pathogenesis of serotype V group B Streptococcus in humans
人类血清型 B 型链球菌的进化和发病机制
- 批准号:
10217675 - 财政年份:2021
- 资助金额:
$ 31.18万 - 项目类别:
Defining novel mechanisms of clonal emergence in Group A Streptococcus
定义 A 组链球菌克隆出现的新机制
- 批准号:
10368151 - 财政年份:2021
- 资助金额:
$ 31.18万 - 项目类别:
Texas Medical Center Training Program in Antimicrobial Resistance
德克萨斯医学中心抗菌素耐药性培训计划
- 批准号:
10621908 - 财政年份:2019
- 资助金额:
$ 31.18万 - 项目类别:
Texas Medical Center Training Program in Antimicrobial Resistance
德克萨斯医学中心抗菌素耐药性培训计划
- 批准号:
10160768 - 财政年份:2019
- 资助金额:
$ 31.18万 - 项目类别:
Contribution of LiaFSR to pathogenesis and carriage of group A Streptococcus
LiaFSR 对 A 族链球菌发病机制和携带的贡献
- 批准号:
9605689 - 财政年份:2017
- 资助金额:
$ 31.18万 - 项目类别:
Contribution of LiaFSR to pathogenesis and carriage of group A Streptococcus
LiaFSR 对 A 族链球菌发病机制和携带的贡献
- 批准号:
10082424 - 财政年份:2017
- 资助金额:
$ 31.18万 - 项目类别:
相似海外基金
Texas Medical Center Training Program in Antimicrobial Resistance
德克萨斯医学中心抗菌素耐药性培训计划
- 批准号:
10621908 - 财政年份:2019
- 资助金额:
$ 31.18万 - 项目类别:
Texas Medical Center Training Program in Antimicrobial Resistance
德克萨斯医学中心抗菌素耐药性培训计划
- 批准号:
9790255 - 财政年份:2019
- 资助金额:
$ 31.18万 - 项目类别:
Texas Medical Center Training Program in Antimicrobial Resistance
德克萨斯医学中心抗菌素耐药性培训计划
- 批准号:
10160768 - 财政年份:2019
- 资助金额:
$ 31.18万 - 项目类别:
The University of Texas Southwestern Medical Center SPORE in Kidney Cancer
德克萨斯大学西南医学中心 SPORE 在肾癌中的应用
- 批准号:
9071063 - 财政年份:2016
- 资助金额:
$ 31.18万 - 项目类别:
The University of Texas Southwestern Medical Center SPORE in Kidney Cancer
德克萨斯大学西南医学中心 SPORE 在肾癌中的应用
- 批准号:
9752982 - 财政年份:2016
- 资助金额:
$ 31.18万 - 项目类别:
University of Texas Southwestern Medical Center SPORE in Kidney Cancer
德克萨斯大学西南医学中心 SPORE 在肾癌中的应用
- 批准号:
10706530 - 财政年份:2016
- 资助金额:
$ 31.18万 - 项目类别:
CC*DNI Networking Infrastructure: Enabling Frictionless Scientific Data Transfers in the Texas Medical Center
CC*DNI 网络基础设施:在德克萨斯医疗中心实现无摩擦的科学数据传输
- 批准号:
1541075 - 财政年份:2015
- 资助金额:
$ 31.18万 - 项目类别:
Standard Grant
The Texas Medical Center Regional Coordinating Center for Heart Failure
德克萨斯医疗中心心力衰竭区域协调中心
- 批准号:
7114589 - 财政年份:2006
- 资助金额:
$ 31.18万 - 项目类别:
The Texas Medical Center Regional Coordinating Center for Heart Failure
德克萨斯医疗中心心力衰竭区域协调中心
- 批准号:
7486279 - 财政年份:2006
- 资助金额:
$ 31.18万 - 项目类别:
The Texas Medical Center Regional Coordinating Center for Heart Failure
德克萨斯医疗中心心力衰竭区域协调中心
- 批准号:
7653701 - 财政年份:2006
- 资助金额:
$ 31.18万 - 项目类别: